{"product_id":"jcrpharm-pestle-analysis","title":"JCR Pharmaceuticals PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUncover the critical political, economic, social, technological, environmental, and legal factors shaping JCR Pharmaceuticals's trajectory. Our expertly crafted PESTLE analysis provides a clear roadmap of external influences, empowering you to anticipate challenges and seize opportunities. Don't navigate the complex pharmaceutical landscape blindfolded; download the full PESTLE analysis now for actionable intelligence and a decisive competitive advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Support for Rare Diseases and Regenerative Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernments globally, with a notable focus in Japan, are increasingly providing robust support for rare disease and regenerative medicine advancements. This backing often materializes through direct subsidies and strategic policy frameworks designed to accelerate development and manufacturing. JCR Pharmaceuticals' selection for Japan's Ministry of Economy, Trade and Industry's 'Regenerative CDMO Subsidy' on July 15, 2025, exemplifies this trend, directly aiding its expansion of biomanufacturing capacity for cutting-edge therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Alignment and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal regulatory alignment significantly impacts JCR Pharmaceuticals' ability to launch rare disease treatments worldwide. Navigating differing approval pathways and market access conditions across regions like the US, Europe, and Latin America is crucial for expanding patient reach.\u003c\/p\u003e\n\u003cp\u003eJCR's strategy involves adapting to diverse political landscapes and healthcare systems, aiming for streamlined clinical trials and regulatory submissions. This adaptation is key to ensuring their innovative therapies reach a wider patient population, with an estimated 7,000 rare diseases affecting millions globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Healthcare Policies on Drug Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment healthcare policies and pricing regulations for pharmaceutical products directly impact revenue generation for biopharmaceutical companies like JCR Pharmaceuticals.  These policies necessitate adaptation of market strategies and cost structures for financial viability.\u003c\/p\u003e\n\u003cp\u003eJCR's sales forecast for GROWJECT® (recombinant human growth hormone) factored in a volume increase despite an NHI price revision in April 2023, highlighting the potential impact of national health insurance pricing on profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Licensing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical stability and international relations are crucial for JCR Pharmaceuticals' overseas licensing agreements, a key revenue stream. For instance, the company revised its fiscal year 2025 forecasts partly due to a stalled licensing deal for JR-171. This highlights how geopolitical shifts and trade policies can directly affect global expansion and financial results.\u003c\/p\u003e\n\u003cp\u003eJCR Pharmaceuticals' financial performance is sensitive to international trade dynamics and the successful negotiation of licensing deals. The company's forecast adjustments for the fiscal year ending March 31, 2025, underscore the impact of these agreements. Geopolitical tensions and evolving trade policies can create significant headwinds for global business development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eImpact of Political Stability:\u003c\/strong\u003e Unstable political environments can delay or prevent the finalization of international licensing agreements, directly affecting revenue projections.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eJR-171 Licensing Deal:\u003c\/strong\u003e JCR Pharmaceuticals' revision of its fiscal year 2025 outlook was partly attributed to the non-conclusion of an overseas licensing agreement for JR-171, demonstrating a tangible financial consequence.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeopolitical and Trade Policy Influence:\u003c\/strong\u003e Global business development and financial performance are intrinsically linked to geopolitical challenges and the prevailing trade policies of various nations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Initiatives and Disease Awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment and public health organizations' efforts to boost disease awareness directly influence the market landscape for pharmaceutical companies. Increased awareness can translate into greater patient demand for diagnostic tools and treatments, creating a more favorable environment for companies like JCR Pharmaceuticals.  For instance, JCR Pharmaceuticals' commitment to Rare Disease Day in Japan, highlighting conditions such as Mucopolysaccharidosis type II (MPS II), directly supports public health objectives by fostering understanding and engagement within patient communities.\u003c\/p\u003e\n\u003cp\u003eThis proactive engagement with public health initiatives can significantly impact treatment adoption rates. By aligning with national health priorities and contributing to patient education, JCR Pharmaceuticals can cultivate a more receptive environment for its therapeutic solutions.  In 2024, Japan’s Ministry of Health, Labour and Welfare continued to emphasize rare disease support, with a reported 10% increase in funding allocated to rare disease research and patient support programs compared to 2023, underscoring the growing governmental focus.\u003c\/p\u003e\n\u003cp\u003eThe public health sector's role in disease awareness campaigns is crucial for JCR Pharmaceuticals. Their initiatives, such as those supporting Rare Disease Day, not only educate the public but also build trust and credibility for the company. This can lead to faster market penetration and better patient access to innovative therapies.  As of early 2025, surveys indicated that public awareness of rare genetic disorders in Japan had risen by approximately 15% over the past two years, partly due to sustained awareness campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Support Shapes Rare Disease Biomanufacturing and Global Deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment support for rare diseases, like JCR Pharmaceuticals' selection for a regenerative CDMO subsidy in July 2025, directly aids biomanufacturing capacity. Political stability is vital for international licensing, as evidenced by JCR's revised 2025 forecasts due to a stalled JR-171 deal. Public health initiatives and disease awareness campaigns, supported by governments, can increase demand for JCR's therapies, with Japan allocating a reported 10% increase in rare disease funding in 2024.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis PESTLE analysis provides a comprehensive examination of the external macro-environmental factors influencing JCR Pharmaceuticals, covering Political, Economic, Social, Technological, Environmental, and Legal dimensions.\u003c\/p\u003e\n\u003cp\u003eIt offers forward-looking insights and actionable strategies to navigate the complex landscape and capitalize on emerging opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise version that can be dropped into PowerPoints or used in group planning sessions, simplifying complex JCR Pharmaceuticals PESTLE analysis for strategic discussions.\u003c\/p\u003e\n\u003cp\u003eEasily shareable summary format ideal for quick alignment across teams or departments, making the JCR Pharmaceuticals PESTLE analysis accessible and actionable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe global rare disease treatment market is a rapidly expanding sector, offering considerable potential for companies like JCR Pharmaceuticals. Projections indicate the market will reach an impressive USD 426.03 billion by 2030, growing at a compound annual growth rate of 11.93%.\u003c\/p\u003e\n\u003cp\u003eThis robust growth is fueled by several key factors. There's a rising awareness and diagnosis of rare diseases, alongside significant breakthroughs in developing innovative treatments, particularly advanced biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals places a significant emphasis on research and development, channeling substantial resources into its pipeline, especially for rare and ultra-rare diseases. This strategic focus is a cornerstone of its long-term growth strategy.\u003c\/p\u003e\n\u003cp\u003eIn fiscal year 2023, the company demonstrated this commitment by increasing its research and development expenses by a notable 27.6% compared to the previous year. These investments are vital for creating innovative therapies.\u003c\/p\u003e\n\u003cp\u003eWhile these ongoing R\u0026amp;D expenditures can affect immediate profitability, they are essential for JCR Pharmaceuticals to develop next-generation treatments and maintain its competitive edge in the biopharmaceutical sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Performance and Forecast Revisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals recently adjusted its financial outlook, revising consolidated earnings forecasts for the fiscal year ending March 31, 2025. This downward revision in net sales stems from higher manufacturing and R\u0026amp;D expenditures, alongside the deferral of a key licensing agreement.\u003c\/p\u003e\n\u003cp\u003eDespite these headwinds, JCR Pharmaceuticals is projecting growth for its flagship products, including IZCARGO®. Looking ahead to the fiscal year ending March 31, 2026, the company anticipates a reduction in its cost of sales, signaling a potential improvement in operational efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Expansion and Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJCR Pharmaceuticals is actively pursuing global expansion, targeting key markets such as the United States, Europe, and Latin America. This strategic move is designed to diversify revenue streams and mitigate risks associated with over-reliance on any single geographic region. For instance, the US pharmaceutical market alone was valued at approximately $577 billion in 2023, representing a significant opportunity for growth.\u003c\/p\u003e\n\u003cp\u003eHowever, this international push necessitates substantial financial investment. JCR must allocate considerable capital towards navigating complex clinical trial requirements, securing diverse regulatory approvals, and building robust commercial infrastructures in each new territory. The company’s investment in Contract Development and Manufacturing Organizations (CDMOs) and the establishment of a global supply chain are critical components of this expansion strategy, aiming to support increased production and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Diversification:\u003c\/strong\u003e Entering markets like the US and EU reduces dependence on Japan, where JCR reported ¥73.9 billion in sales for fiscal year 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestment Needs:\u003c\/strong\u003e Global expansion requires significant capital for clinical trials and regulatory submissions, which can run into hundreds of millions of dollars per drug candidate.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSupply Chain Development:\u003c\/strong\u003e JCR's investment in CDMOs aims to secure manufacturing capacity, crucial for meeting demand in new international markets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Hurdles:\u003c\/strong\u003e Gaining approval from bodies like the FDA and EMA is a lengthy and costly process, often taking several years and millions in expenditure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of Manufacturing and Supply Chain Resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFluctuations in manufacturing costs, such as the disposal of materials, directly affect JCR Pharmaceuticals' bottom line. The company's FY2025 financial forecast revision highlighted an increase in the cost of sales, partly due to higher disposal expenses for manufacturing materials.\u003c\/p\u003e\n\u003cp\u003eTo mitigate these pressures, JCR is actively building a robust global supply chain capable of withstanding emergencies. This strategic move includes significant investments in new facilities, aiming to guarantee a consistent and dependable long-term supply of its products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Disposal Costs:\u003c\/strong\u003e JCR's FY2025 forecast revision cited higher disposal costs for manufacturing materials as a factor impacting its cost of sales.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSupply Chain Resilience Investment:\u003c\/strong\u003e The company is investing in constructing a resilient global supply chain for emergency preparedness.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFacility Expansion:\u003c\/strong\u003e JCR is also investing in new facilities to ensure stable and long-term product availability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Factors Reshape Pharma's Global Strategy \u0026amp; Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic factors significantly influence JCR Pharmaceuticals' financial performance and strategic decisions. The company's revised financial outlook for fiscal year 2025, reflecting increased manufacturing and R\u0026amp;D expenditures, underscores the impact of rising operational costs.\u003c\/p\u003e\n\u003cp\u003eThese increased costs, including those related to the disposal of manufacturing materials, directly affect JCR's profitability. The company's strategic investments in building a resilient global supply chain and expanding facilities are aimed at mitigating these economic pressures and ensuring long-term product availability.\u003c\/p\u003e\n\u003cp\u003eJCR Pharmaceuticals' global expansion strategy, targeting markets like the US and Europe, is also heavily influenced by economic conditions and the substantial capital required for clinical trials and regulatory approvals in these regions.\u003c\/p\u003e\n\u003cp\u003eThe company's sales performance in Japan for fiscal year 2024 reached ¥73.9 billion, highlighting the importance of its domestic market while it simultaneously navigates the economic landscape of international expansion.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eJCR Pharmaceuticals PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. This comprehensive JCR Pharmaceuticals PESTLE analysis delves into the Political, Economic, Social, Technological, Legal, and Environmental factors impacting the company. Gain a strategic understanding of the external forces shaping JCR Pharmaceuticals' operations and future trajectory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611908194681,"sku":"jcrpharm-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jcrpharm-pestle-analysis.png?v=1754765323","url":"https:\/\/matrixbcg.com\/products\/jcrpharm-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}